FMD will host a webinar on how to leverage the regulatory reform in China to accelerate global drug development. Dr. Dan Zhang and Emil Fu will discuss the regulatory reform in China and the strategies biopharm companies can take to make your programs more efficient.
Title: Leverage the Regulatory Changes in China to Accelerate Global Drug Development Program
Time: Friday, October 5, 12 noon EDT
The regulatory regimes in China has been undergoing a significant overhaul. These changes aiming to align the China system to the ICH standards is causing confusion and misunderstanding. To take full advantage of the new system in China, overseas compaines must plan early to include China in their global development plan to accelerate their product development cycle.
Our industry experts will explore the recent regulatory reforms in China including the new regulations on the acceptance of foreign data by the China National Drug Administration (CNDA) formerly the cFDA. They will focus on the impact on the biopharma industry. Audience will learn how to take full advantage of the reform to accelerate global development.
Dr. Dan Zhang, Executive Chairman of FMD, will discuss the impact of the recent regulatory reform in China. Among other strategic imperatives, Dr. Zhang will delineate the potentials to leverage these favorable changes to accelerate global drug development programs. Limited space is on a first-come-first-serve basis. Registration is open now.